Integra LifeSciences Announces Investor Forum at the American Association of Neurological Surgeons Meeting on April 9, 2002
The Investor Forum is open to the general public and those who wish to attend the Investor Forum in person should send an email to the attention of John Bostjancic (jbostjancic@integra-LS.com) by March 15, 2002 requesting a reservation to attend in person. The live presentations can be accessed via telephone by dialing 706-679-0769 and the live audio and slide presentations from the Investor Forum will also be accessible via a webcast that can be accessed through a link provided on Integra's home page at http://www.Integra-LS.com. Listeners participating via telephone or webcast will not be able to ask questions during the question and answer session.
A replay of the Investor Forum will be available through April 23, 2002 by dialing 706-645-9291 (access code 3391660) or through the webcast.
Integra LifeSciences Holdings Corporation develops, manufactures and markets medical devices, implants and biomaterials primarily used in the treatment of cranial and spinal disorders, soft tissue repair and orthopedics. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. The Company has its corporate headquarters in Plainsboro, New Jersey, with manufacturing and research facilities located throughout the world. The Company has approximately 600 permanent employees.
Statements made in the upcoming Investor Forum may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted results. Forward-looking factors that may be discussed include, but are not limited to, expected financial results, new product development, governmental approvals, market potential, and expected sales and potential therapeutic applications of new products. In addition, the economic, competitive, governmental, technological and other factors identified under the heading ``Risk Factors'' included in the Business section of Integra's Annual Report on Form 10-K/A for the year ended December 31, 2000 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
Contact:
Integra LifeSciences Holdings Corporation, Plainsboro
John B. Henneman, III, Senior Vice President
Chief Administrative Officer
609-936-2481
jhenneman@integra-Ls.com
John Bostjancic, Senior Director of Finance
609-936-2239
jbostjancic@integra-Ls.com